Olink Holding AB (Olink Holding AB) Growth Rank : 0 (As of May. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Olink Holding AB Growth Rank?

Olink Holding AB has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Olink Holding AB Growth Rank Related Terms

Thank you for viewing the detailed overview of Olink Holding AB's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Olink Holding AB (Olink Holding AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Olink Holding AB (NAS:OLK) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

6XA:Germany

Address

Uppsala Science Park, Uppsala, SWE, SE-75183

Website

https://www.olink.com

Olink Holding AB has a proprietary and patented Proximity Extension Assay technology, which enables researchers to use one platform for discovery to clinical trials to diagnostic applications utilizing the established infrastructure of labs and installed instrumentation. It has two segments including Kit and Services. It derives revenues from Sweden, the Americas, China, EMEA (Excluding Sweden) Japan, and other regions.